New study investigates memory and mood problems in lung cancer patients on targeted therapy

NCT ID NCT06781905

Recruiting now Knowledge-focused Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at memory, thinking, and mood problems that can happen with certain targeted lung cancer drugs (ALK/ROS1 inhibitors). About 20 patients who have these side effects will undergo detailed brain and psychiatric tests. The goal is to better understand these issues and create a care plan that involves patients and researchers working together.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cognitive disorder lung neoplasm metastatic malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC LUNG CANCER METASTATIC LUNG CANCER WITH ALK/ROS1 FUSION

Contacts and locations

Locations

Day care Hospital, Pierre Wertheimer Hospital, Civil Hospitals of Lyon
RECRUITING

Bron, 69500, France
Pneumology service, Louis Pradel Hospital, Civil Hospitals of Lyon
RECRUITING

Bron, 69500, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.